PF-Atlas › Clinical Trials › NCT02445053

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele

ivacaftor · Not specified

Registry ID
NCT02445053
Phase
Not specified
Status
Completed
Drug / intervention
ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2015-04
Enrollment
75
Locations
15

About this trial

To describe the effectiveness of Kalydeco® treatment in patients with cystic fibrosis (CF) who have 1 of 8 non G551D gating CFTR mutations (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D).

View NCT02445053 on ClinicalTrials.gov →

Explore related

All ivacaftor trialsAll IPF trials

Related trials

Ivacaftor — NCT00953706Ivacaftor — NCT01614457Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312ivacaftor — NCT02742519
Medical disclaimer. This page summarizes public trial data for NCT02445053 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.